Moderna, Inc. - Common Stock (MRNA)

Vertex raised its full-year outlook in Q2 with a growing pipeline across multiple disease areas. Moderna’s mRNA flu vaccine just cleared a key FDA hurdle with an expanding oncology pipeline behind it.

Is bigger always better? Not necessarily.

Forget the "Magnificent Seven" in favor of the "Tremendous Three"?

After a few years of stagnation, this stock is soaring.

The biotech could play a significant role in a national effort to combat cancer.

Have Moderna’s shares risen too much, too fast?

Axsome is posting 65% revenue growth but burning cash, while Moderna's vaccine market is cooling yet its oncology pipeline carries transformative potential.

These stocks have all soared more than 350% this year.

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. Lu...

Check out the companies making headlines yesterday: United Therapeutics (NASDAQ:UTHR): Biotechnology company United Therapeutics (NASDAQ:UTHR) rose by 13.6% ...

New investors might be eager to jump in during a bull market.

The company could enter a fresh growth phase.

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 6% in the morning session after Citigroup downgraded the company to Sell from Neutr...